Darwin Wealth Management’s Travere Therapeutics TVTX Stock Holding History

Darwin Wealth Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$87	Buy	+1	New	+$61	﹤0.01%	1144

Other funds holding TVTX

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Stephens Investment Management Group Houston, Texas $9.29B AUM 41.16% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.64B AUM 71.19% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.45B AUM 70.46% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $25.3B AUM 15.9% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Darwin Wealth Management's TVTX Position: Q3 2026 in Review

Darwin Wealth Management opened a new position in Travere Therapeutics (TVTX) in Q3 2026: 1 share worth $87. The stake represents ﹤0.01% of the portfolio and ranks #1144 among its holdings.

158 funds tracked by Wall St. Rank hold TVTX as of Q3 2026.

Darwin Wealth Management held 1 share of Travere Therapeutics worth $87 as of Q3 2026.
Travere Therapeutics was a new Darwin Wealth Management position in Q3 2026.
Travere Therapeutics made up ﹤0.01% of Darwin Wealth Management's portfolio in Q3 2026, its #1144 holding.
158 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2026.

Based on Darwin Wealth Management's 13F filing for Q3 2026, filed 9 Nov 2026.